C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant to treat melanoma, colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC under preclinical stage. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA, Darmstadt, Germany; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Period	Debt/Equity
2020-12-31	0.43
2021-12-31	0.30
2022-12-31	0.49
2023-12-31	0.53
2024-12-31	0.62

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CCCC	$2.90	+5.66%	1.37M
3
4
5

C4 Therapeutics Inc. (CCCC) Debt to Equity Ratio

Debt to Equity Ratio Data

Get C4 Therapeutics Inc. Data in Excel

More CCCC Financial Data